Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 36Leukemia, Myeloid, Acute 27Colorectal Neoplasms 27Neoplasms 26Neoplasm Metastasis 22Recurrence 21Multiple Myeloma 20Advanced Solid Tumors 20Lymphoma, B-Cell 19Breast Neoplasms 18Pancreatic Neoplasms 14Lung Neoplasms 13Glioblastoma 13Carcinoma, Hepatocellular 13Lymphoma 12Brain Neoplasms 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Hematologic Neoplasms 11Glioma 11Squamous Cell Carcinoma of Head and Neck 10Ovarian Neoplasms 10Melanoma 10Leukemia 10Advanced Solid Tumor 10Triple Negative Breast Neoplasms 9Prostatic Neoplasms 9Head and Neck Neoplasms 9Lymphoma, Non-Hodgkin 8Esophageal Neoplasms 8Myelodysplastic Syndromes 7

Interventions

lorlatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Not yet recruiting × ALK Positive Non-small Cell Lung Cancer × Clear all
NCT07617337 2026-06-01

AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer

Chugai Pharmaceutical

Phase 1 Not yet recruiting
102 enrolled
Thoracic

ALK Positive Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡